The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: A randomised, double-blind, placebo-controlled trial

I. K. Wang, Y. Y. Wu, Y. F. Yang, I. W. Ting, C. C. Lin, T. H. Yen, J. H. Chen, C. H. Wang, C. C. Huang, H. C. Lin

研究成果: 雜誌貢獻文章

60 引文 (Scopus)

摘要

Inflammatory markers such as interleukin (IL)-6 and tumour necrosis factor-alpha (TNF-α) are elevated in dialysis patients and can predict cardiovascular events and all-cause mortality. Endotoxin is an important source and also another marker of inflammation in patients with chronic kidney disease. The aim of this study was to evaluate the impact of oral probiotics on serum levels of endotoxemia and cytokines in peritoneal dialysis (PD) patients. The decline of residual renal function, peritonitis episodes, and cardiovascular events were also recorded. From July 2011 to June 2012, a randomised, double-blind, placebo-controlled trial was conducted in PD patients. The intervention group received one capsule of probiotics containing 109 cfu Bifobacterium bifidum A218, 109 cfu Bifidobacterium catenulatum A302, 109 cfu Bifidobacterium longum A101, and 109 cfu Lactobacillus plantarum A87 daily for six months, while the placebo group received similar capsules containing maltodextrin for the same duration. Levels of serum TNF-α, interferon gamma, IL-5, IL-6, IL-10, IL-17, and endotoxin were measured before and six months after intervention. 39 patients completed the study (21 in the probiotics group and 18 in the placebo group). In patients receiving probiotics, levels of serum TNF-α, IL-5, IL-6, and endotoxin significantly decreased after six months of treatment, while levels of serum IL-10 significantly increased. In contrast, there were no significant changes in levels of serum cytokines and endotoxin in the placebo group after six months. In addition, the residual renal function was preserved in patients receiving probiotics. In conclusion, probiotics could significantly reduce the serum levels of endotoxin, pro-inflammatory cytokines (TNF-α and IL-6), IL-5, increase the serum levels of anti-inflammatory cytokine (IL-10), and preserve residual renal function in PD patients.

原文英語
頁(從 - 到)423-430
頁數8
期刊Beneficial microbes
6
發行號4
DOIs
出版狀態已發佈 - 2015

指紋

Probiotics
Peritoneal Dialysis
Endotoxins
Placebos
Cytokines
Serum
Interleukin-6
Interleukin-5
Tumor Necrosis Factor-alpha
Interleukin-10
lonomycin
Kidney
N-phenylacetoaminomethylene-DL-p-nitrophenylalanine
Capsules
Lactobacillus plantarum
Bifidobacterium
Endotoxemia
Interleukin-17
Peritonitis
Chronic Renal Insufficiency

ASJC Scopus subject areas

  • Microbiology (medical)
  • Microbiology

引用此文

The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients : A randomised, double-blind, placebo-controlled trial. / Wang, I. K.; Wu, Y. Y.; Yang, Y. F.; Ting, I. W.; Lin, C. C.; Yen, T. H.; Chen, J. H.; Wang, C. H.; Huang, C. C.; Lin, H. C.

於: Beneficial microbes, 卷 6, 編號 4, 2015, p. 423-430.

研究成果: 雜誌貢獻文章

Wang, I. K. ; Wu, Y. Y. ; Yang, Y. F. ; Ting, I. W. ; Lin, C. C. ; Yen, T. H. ; Chen, J. H. ; Wang, C. H. ; Huang, C. C. ; Lin, H. C. / The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients : A randomised, double-blind, placebo-controlled trial. 於: Beneficial microbes. 2015 ; 卷 6, 編號 4. 頁 423-430.
@article{5116f80281ec49da8a1683bb61dd24de,
title = "The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients: A randomised, double-blind, placebo-controlled trial",
abstract = "Inflammatory markers such as interleukin (IL)-6 and tumour necrosis factor-alpha (TNF-α) are elevated in dialysis patients and can predict cardiovascular events and all-cause mortality. Endotoxin is an important source and also another marker of inflammation in patients with chronic kidney disease. The aim of this study was to evaluate the impact of oral probiotics on serum levels of endotoxemia and cytokines in peritoneal dialysis (PD) patients. The decline of residual renal function, peritonitis episodes, and cardiovascular events were also recorded. From July 2011 to June 2012, a randomised, double-blind, placebo-controlled trial was conducted in PD patients. The intervention group received one capsule of probiotics containing 109 cfu Bifobacterium bifidum A218, 109 cfu Bifidobacterium catenulatum A302, 109 cfu Bifidobacterium longum A101, and 109 cfu Lactobacillus plantarum A87 daily for six months, while the placebo group received similar capsules containing maltodextrin for the same duration. Levels of serum TNF-α, interferon gamma, IL-5, IL-6, IL-10, IL-17, and endotoxin were measured before and six months after intervention. 39 patients completed the study (21 in the probiotics group and 18 in the placebo group). In patients receiving probiotics, levels of serum TNF-α, IL-5, IL-6, and endotoxin significantly decreased after six months of treatment, while levels of serum IL-10 significantly increased. In contrast, there were no significant changes in levels of serum cytokines and endotoxin in the placebo group after six months. In addition, the residual renal function was preserved in patients receiving probiotics. In conclusion, probiotics could significantly reduce the serum levels of endotoxin, pro-inflammatory cytokines (TNF-α and IL-6), IL-5, increase the serum levels of anti-inflammatory cytokine (IL-10), and preserve residual renal function in PD patients.",
keywords = "Cytokines, Endotoxin, Inflammation, Peritoneal dialysis, Probiotics",
author = "Wang, {I. K.} and Wu, {Y. Y.} and Yang, {Y. F.} and Ting, {I. W.} and Lin, {C. C.} and Yen, {T. H.} and Chen, {J. H.} and Wang, {C. H.} and Huang, {C. C.} and Lin, {H. C.}",
year = "2015",
doi = "10.3920/BM2014.0088",
language = "English",
volume = "6",
pages = "423--430",
journal = "Beneficial microbes",
issn = "1876-2883",
publisher = "Wageningen Academic Publishers",
number = "4",

}

TY - JOUR

T1 - The effect of probiotics on serum levels of cytokine and endotoxin in peritoneal dialysis patients

T2 - A randomised, double-blind, placebo-controlled trial

AU - Wang, I. K.

AU - Wu, Y. Y.

AU - Yang, Y. F.

AU - Ting, I. W.

AU - Lin, C. C.

AU - Yen, T. H.

AU - Chen, J. H.

AU - Wang, C. H.

AU - Huang, C. C.

AU - Lin, H. C.

PY - 2015

Y1 - 2015

N2 - Inflammatory markers such as interleukin (IL)-6 and tumour necrosis factor-alpha (TNF-α) are elevated in dialysis patients and can predict cardiovascular events and all-cause mortality. Endotoxin is an important source and also another marker of inflammation in patients with chronic kidney disease. The aim of this study was to evaluate the impact of oral probiotics on serum levels of endotoxemia and cytokines in peritoneal dialysis (PD) patients. The decline of residual renal function, peritonitis episodes, and cardiovascular events were also recorded. From July 2011 to June 2012, a randomised, double-blind, placebo-controlled trial was conducted in PD patients. The intervention group received one capsule of probiotics containing 109 cfu Bifobacterium bifidum A218, 109 cfu Bifidobacterium catenulatum A302, 109 cfu Bifidobacterium longum A101, and 109 cfu Lactobacillus plantarum A87 daily for six months, while the placebo group received similar capsules containing maltodextrin for the same duration. Levels of serum TNF-α, interferon gamma, IL-5, IL-6, IL-10, IL-17, and endotoxin were measured before and six months after intervention. 39 patients completed the study (21 in the probiotics group and 18 in the placebo group). In patients receiving probiotics, levels of serum TNF-α, IL-5, IL-6, and endotoxin significantly decreased after six months of treatment, while levels of serum IL-10 significantly increased. In contrast, there were no significant changes in levels of serum cytokines and endotoxin in the placebo group after six months. In addition, the residual renal function was preserved in patients receiving probiotics. In conclusion, probiotics could significantly reduce the serum levels of endotoxin, pro-inflammatory cytokines (TNF-α and IL-6), IL-5, increase the serum levels of anti-inflammatory cytokine (IL-10), and preserve residual renal function in PD patients.

AB - Inflammatory markers such as interleukin (IL)-6 and tumour necrosis factor-alpha (TNF-α) are elevated in dialysis patients and can predict cardiovascular events and all-cause mortality. Endotoxin is an important source and also another marker of inflammation in patients with chronic kidney disease. The aim of this study was to evaluate the impact of oral probiotics on serum levels of endotoxemia and cytokines in peritoneal dialysis (PD) patients. The decline of residual renal function, peritonitis episodes, and cardiovascular events were also recorded. From July 2011 to June 2012, a randomised, double-blind, placebo-controlled trial was conducted in PD patients. The intervention group received one capsule of probiotics containing 109 cfu Bifobacterium bifidum A218, 109 cfu Bifidobacterium catenulatum A302, 109 cfu Bifidobacterium longum A101, and 109 cfu Lactobacillus plantarum A87 daily for six months, while the placebo group received similar capsules containing maltodextrin for the same duration. Levels of serum TNF-α, interferon gamma, IL-5, IL-6, IL-10, IL-17, and endotoxin were measured before and six months after intervention. 39 patients completed the study (21 in the probiotics group and 18 in the placebo group). In patients receiving probiotics, levels of serum TNF-α, IL-5, IL-6, and endotoxin significantly decreased after six months of treatment, while levels of serum IL-10 significantly increased. In contrast, there were no significant changes in levels of serum cytokines and endotoxin in the placebo group after six months. In addition, the residual renal function was preserved in patients receiving probiotics. In conclusion, probiotics could significantly reduce the serum levels of endotoxin, pro-inflammatory cytokines (TNF-α and IL-6), IL-5, increase the serum levels of anti-inflammatory cytokine (IL-10), and preserve residual renal function in PD patients.

KW - Cytokines

KW - Endotoxin

KW - Inflammation

KW - Peritoneal dialysis

KW - Probiotics

UR - http://www.scopus.com/inward/record.url?scp=84931326458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931326458&partnerID=8YFLogxK

U2 - 10.3920/BM2014.0088

DO - 10.3920/BM2014.0088

M3 - Article

C2 - 25609654

AN - SCOPUS:84931326458

VL - 6

SP - 423

EP - 430

JO - Beneficial microbes

JF - Beneficial microbes

SN - 1876-2883

IS - 4

ER -